Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤300,000-share inducement option granted to new non-executive employee
- ➤$3.92 exercise price matched Annexon’s November 13 closing price
- ➤Option vests over four years, subject to continued employment
- ➤Annexon targets neuroinflammatory diseases affecting nearly 10 million people worldwide
BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on November 14, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 300,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $3.92, which was the closing price of Annexon’s common stock on November 13, 2026, the trading day immediately preceding the date of grant, and vest over 4 years, with 25% of the shares underlying the option vesting on the first anniversary of the employment start date and an additional 1/48th of the shares vesting monthly thereafter, subject to such employee’s continued service through the applicable vesting dates.
Get started
Create a free account to read the full story.
